Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$13.97
-0.6%		$13.18
$6.62
▼
$15.35
$1.35B1.27684,186 shs824,112 shs
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
$12.74
-3.0%		$12.16
$7.23
▼
$14.93
$1.36B11.09 million shs916,440 shs
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
$3.72
-0.8%		$3.74
$1.85
▼
$5.15
$341.20M0.53312,895 shs161,591 shs
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
$24.24
-2.1%		$21.10
$6.50
▼
$49.95
$1.46B1.71739,924 shs538,761 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-0.64%-1.20%+13.67%+55.22%+90.59%
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
-2.97%-7.28%-5.42%+69.87%+20.19%
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
-0.80%-5.34%-3.38%+10.06%+60.34%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
-2.10%+3.02%+8.94%+84.19%-39.40%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$13.97
-0.6%		$13.18
$6.62
▼
$15.35
$1.35B1.27684,186 shs824,112 shs
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
$12.74
-3.0%		$12.16
$7.23
▼
$14.93
$1.36B11.09 million shs916,440 shs
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
$3.72
-0.8%		$3.74
$1.85
▼
$5.15
$341.20M0.53312,895 shs161,591 shs
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
$24.24
-2.1%		$21.10
$6.50
▼
$49.95
$1.46B1.71739,924 shs538,761 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-0.64%-1.20%+13.67%+55.22%+90.59%
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
-2.97%-7.28%-5.42%+69.87%+20.19%
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
-0.80%-5.34%-3.38%+10.06%+60.34%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
-2.10%+3.02%+8.94%+84.19%-39.40%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
3.00
Buy$26.1787.31% Upside
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
2.79
Moderate Buy$19.6053.85% Upside
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
2.73
Moderate Buy$12.00222.58% Upside
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
2.82
Moderate Buy$43.3878.94% Upside

Current Analyst Ratings Breakdown

Latest SABS, ORIC, VOR, and MGTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/20/2026
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/14/2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$26.00 ➝ $27.00
8/13/2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
8/12/2026
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$18.00 ➝ $27.00
8/11/2026
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D-) ➝ Sell (D+)
8/10/2026
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$25.00 ➝ $27.00
8/6/2026
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D+) ➝ Sell (E+)
7/17/2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/17/2026
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/8/2026
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D+)
7/8/2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$25.00 ➝ $26.00
(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$81.39M16.48N/AN/A$2.25 per share6.21
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
N/AN/AN/AN/A$3.68 per shareN/A
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
$1.32M256.43$0.34 per share10.98$2.36 per share1.58
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$114.20M$0.7119.68N/AN/A19.87%283.85%29.39%11/12/2026 (Estimated)
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
-$129.47M-$1.35N/AN/AN/AN/A-35.35%-33.39%11/12/2026 (Estimated)
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
$13.27M-$1.30N/AN/AN/AN/A-6.74%-6.06%11/13/2026 (Estimated)
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest SABS, ORIC, VOR, and MGTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$0.4583$1.71+$2.1683$1.71$0.70 million$321.43 million
8/11/2026Q2 2026
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
-$0.69-$0.80-$0.11-$1.16N/AN/A
8/6/2026Q2 2026
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
-$0.2830-$0.28+$0.0030-$0.28$0.13 millionN/A
8/3/2026Q2 2026
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
-$0.3594-$0.38-$0.0207-$0.38N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
N/AN/AN/AN/AN/A
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
N/AN/AN/AN/AN/A
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
N/AN/AN/AN/AN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
0.46
3.76
3.76
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
N/A
13.19
13.19
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
0.01
9.22
9.22
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
67.48%
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
95.05%
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
7.82%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
97.29%

Insider Ownership

CompanyInsider Ownership
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
7.40%
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
5.70%
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
7.39%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
0.27%
CompanyEmployeesShares OutstandingFree FloatOptionable
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
30096.04 million88.94 millionOptionable
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
80103.65 million97.75 millionOptionable
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
14090.99 million84.26 millionNot Optionable
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
14059.16 million59.00 millionN/A

Recent News About These Companies

Braidwell LP Has $10.55 Million Stake in Vor Biopharma Inc. $VOR
September 3 at 4:39 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-braidwell-lp-has-1055-million-stake-in-vor-biopharma-inc-vor-2026-09-03/
Bank of America Corp DE Has $2.01 Million Stock Holdings in Vor Biopharma Inc. $VOR
September 3 at 3:12 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-has-201-million-stock-holdings-in-vor-biopharma-inc-vor-2026-09-03/
Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Recommendation of "Moderate Buy" from Analysts
September 3 at 2:44 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31000130
Vor Biopharma Inc. (NASDAQ:VOR) Given Average Recommendation of "Moderate Buy" by Brokerages
September 3 at 2:43 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-vor-biopharma-inc-nasdaq-vor-given-average-recommendation-of-moderate-buy-by-brokerages-2026-09-03/
Vor Biopharma (NASDAQ:VOR) Stock Price Up 6.2% - Time to Buy?
September 2 at 11:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-vor-biopharma-nasdaq-vor-stock-price-up-62-time-to-buy-2026-09-02/
Vor Bio To Participate in Upcoming September Conferences
September 1 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/01/3354086/0/en/vor-bio-to-participate-in-upcoming-september-conferences.html
Wall Street Zen Upgrades Vor Biopharma (NASDAQ:VOR) to Hold
August 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/wall-street-zen-upgrades-vor-biopharma-nasdaqvor-to-hold-2026-08-15/
Q3 EPS Estimates for Vor Biopharma Reduced by HC Wainwright
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/q3-eps-estimates-for-vor-biopharma-reduced-by-hc-wainwright-2026-08-14/
Vor Biopharma FY2030 EPS Forecast Reduced by HC Wainwright
August 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/vor-biopharma-fy2030-eps-forecast-reduced-by-hc-wainwright-2026-08-13/
Wedbush Issues Positive Forecast for Vor Biopharma (NASDAQ:VOR) Stock Price
August 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/wedbush-issues-positive-forecast-for-vor-biopharma-nasdaqvor-stock-price-2026-08-12/
Vor Biopharma (NASDAQ:VOR) Trading Down 6.5% on Disappointing Earnings
August 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/vor-biopharma-nasdaqvor-trading-down-65-on-disappointing-earnings-2026-08-12/
Vor Biopharma Shares Drop After Q2 Results
August 11, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vor-biopharma-shares-drop-q2-140534024.html
Vor Biopharma (NASDAQ:VOR) Posts Earnings Results
August 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/vor-biopharma-nasdaqvor-posts-earnings-results-2026-08-11/
Vor Biopharma: Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 11, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69277816-vor-biopharma-vor-bio-reports-second-quarter-2026-financial-results-and-provides-corporate-update-399.htm
Renaissance Technologies LLC Makes New $2.30 Million Investment in Vor Biopharma Inc. $VOR
August 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-renaissance-technologies-llc-makes-new-230-million-investment-in-vor-biopharma-inc-vor-2026-08-11/
Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Rating of "Moderate Buy" from Analysts
August 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/vor-biopharma-inc-nasdaqvor-receives-consensus-rating-of-moderate-buy-from-analysts-2026-08-09/
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/03/3337912/0/en/vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html
Vor Biopharma: Vor Bio Appoints David Zaccardelli to Board of Directors
July 8, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/68970529-vor-biopharma-vor-bio-appoints-david-zaccardelli-to-board-of-directors-399.htm
Vor Bio Appoints David Zaccardelli to Board of Directors
July 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/07/3323613/0/en/vor-bio-appoints-david-zaccardelli-to-board-of-directors.html
Vor Biopharma: A Financed Autoimmune Pivot With More Substance Than The Market Realizes
July 7, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4920412-vor-biopharma-a-financed-autoimmune-pivot-with-more-substance-than-the-market-realizes
Vor Biopharma Stock Short Interest Report | NASDAQ:VOR | Benzinga
July 3, 2026  |  benzinga.comhttps://www.benzinga.com/quote/VOR/short-interest

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Magnifying glass highlighting glowing candlestick chart bars against a dark background with an upward trending stock price line.
3 Overlooked Stocks Analysts Still Like as AI Trades Get Crowded
By Nathan Reiff | August 11, 2026
Computer monitor on a desk displaying a candlestick stock price chart showing a decline followed by an upward rebound.
3 Contrarian Trades for a Market That Looks Too Hot
By Bridget Bennett | August 25, 2026
Illustration of a satellite beaming signal to a smartphone and cell tower above a city skyline at dusk.
Space Race Meets Ground Reality for Tower REITs
By Jeffrey Neal Johnson | September 1, 2026
Dell logo illuminated in a data center setting with a laptop and server racks visible nearby.
One of Trump's Favorite Stocks Just Reported Blowout Earnings
By Jessica Mitacek | September 3, 2026
Printed quarterly statement with revenue chart beside a tablet showing a dividend overview chart, on a desk overlooking a city skyline.
These 5 Dividend Stocks Show Why Income Investing Still Matters
By Ryan Hasson | August 17, 2026
MeiraGTx stock logo

MeiraGTx NASDAQ:MGTX

$13.97 -0.09 (-0.64%)
As of 09/3/2026 04:00 PM Eastern

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Oric Pharmaceuticals stock logo

Oric Pharmaceuticals NASDAQ:ORIC

$12.74 -0.39 (-2.97%)
As of 09/3/2026 04:00 PM Eastern

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

SAB Biotherapeutics stock logo

SAB Biotherapeutics NASDAQ:SABS

$3.72 -0.03 (-0.80%)
As of 09/3/2026 04:00 PM Eastern

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.

Vor Biopharma stock logo

Vor Biopharma NASDAQ:VOR

$24.24 -0.52 (-2.10%)
As of 09/3/2026 04:00 PM Eastern

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas